P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

por Frigault, M., Sher, S., Ravikrishnan, J., Izumi, R., Ware, J., Wong, H., Johnson, A., Stelte-Ludwig, B., Byrd, J., Sampath, D., Rogers, K., Woyach, J., Lapalombella, R., Hamdy, A.
Publicado 2022

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TR...

por Mato, A. R., Wierda, W. G., Pagel, J. M., Davids, M. S., Zinzani, P. L., Lu, Y., Liu, H., Shahda, S., Leow, C. C., Tam, C. S., Woyach, J. A., Eyre, T. A.
Publicado 2022

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

por Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech-Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.
Publicado 2022